DNA methylation pattern between patients with HER3+ and HER3- brain metastases. DNA methylation pattern between patients with HER3+ and HER3- brain metastases

HER3 (ErbB3) belongs to a family of receptor tyrosine kinases together with the known oncogenes EGFR and HER2. Recently, antibody drug conjugates (ADCs) targeting these receptors showed promising clinical activity in extracranial malignancies of breast and lung cancer. We aimed to investigate HER3 expression in breast and lung cancer brain metastases (BM) as the basis for future clinical trial design. Illumina MethylationEPIC 850k microarrays were used to analyze genome-wide DNA methylation patterns of HER3-positive (n=43) and HER3-negative (n=28) BM. Overall design: Compare DNA methylation pattern between patients with HER3+ and HER3- brain metastases.